Oral Anticoagulant Therapy in Patients Receiving Haemodialysis: Is It Time to Abandon It?

Table 3

Mortality risk in haemodialysis patients with atrial fibrillation treated with warfarin.

Study	Population (𝑛)	Period (y)	Mortality (HR)
Knoll et al. [36]	𝑛—235 pts	3 years	HR—0.80 (95% CI 0.28–2.29, 𝑃<0.67)
Chan et al. [37]	𝑛—1671 pts	1 year	HR—1.10 (0.94–1.30)
Wizemann et al. [38]	𝑛—17513 pts; (AF—12.5%)	7 years	All ages: HR—1.16 (95% CI 1.08–1.25, 𝑃<0.001)
			Age < 65: HR—1.29 (95% CI 0.45–3.68, 𝑃<0.63)
			Age 65–75: HR—1.35 (95% CI 0.69–2.63, 𝑃<0.39)
			Age > 75: HR—2.17 (95% CI 1.04–4.53, 𝑃<0.04)
Chan et al. [39]	𝑛—41425 pts	11 years
	Warfarin—8.3%		HR—1.73 (95% CI 1.62–1.85)
	Clopidogrel—10%		HR—1.50 (95% CI 1.39–1.62)
	Acetylsalicylic acid—30.4%		HR—1.17 (95% CI 1.12–1.22)
	Acetylsalicylic acid and warfarin—8%		HR—1.11 (95% CI 1.03–1.86)

HR: hazard ratio, CI: confidence interval, 𝑛: number of patients.